HOPE 1 & 2

100% Organic Tincture Developed with Autism Spectrum Disorder Symptoms in Mind.

Pennsylvania

HOPE 1 & 2

100% Olive Oil Tincture Developed with Autism Spectrum Disorder Symptoms in Mind.

Australia

Manufactured by Tasmanian Alkaloids and Distributed by Health House Holdings Ltd.

HOPE 1 & 2

100% Organic Tincture Developed with Autism Spectrum Disorder Symptoms in Mind.

Washington DC

Manufactured and Distributed by Alternative Solutions.

HOPE 1 & 2

100% Organic Tincture Developed with Autism Spectrum Disorder Symptoms in Mind.

Louisiana

For more information on product availability in Louisiana, please see our Dispensaries page or visit IleraHolisticHealthcare.com

What is HOPE?

For families affected by autism spectrum disorder, no two days are identical. The anxiety of a random cluster induced episode can be debilitating. Two FDA approved drugs are available to treat patients suffering from ASD, but autism presents a range of complications instead of siloed endpoints. HOPE was formulated to address the spectrum of challenges associated with autism by collaborating with communities such as HOPE Grows for Autism during the development process to alleviate families from the anxiety of sporadic ASD episodes

Product Features

  • A mild pleasant taste of
    mint chocolate,
    and natural grapefruit.
  • Available as a tincture.
    (cannabis oil)
  • Blended in 100%
    organic olive oil.
  • Autism Patients Report Improvement in Symptoms and Quality of Life with Zelira Therapeutics’ HOPE™

    August 3, 2022 Read More
  • HOPE® 1 Demonstrates Improvements in Clinical Global Impression (CGI) in Patients with Autism Spectrum Disorder

    Read More
  • A Natural History Study of Medical Cannabis Consumption in Pediatric Autism in the United States

    Read More

ABOUT ZELIRA THERAPEUTICS

Zelira Therapeutics Ltd (formerly Zelda Therapeutics) is a leading global therapeutic medicinal cannabis company with access to the world’s largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions. Zelira has launched two proprietary formulations under the HOPE® brand for Autism in multiple US-states with plans to expand into global markets in 2020.

Welcome to ZeliraHOPE.com

Please confirm you are a resident of the United States